Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Sanguine On Market Opportunity Despite Biosimilar Neulasta Setback

Executive Summary

Questions from European regulators around Sandoz's market application for biosimilar pegfilgrastim have prompted the company to withdraw the drug's filing – a delay which could allow competitor biosimilar developers to launch ahead of the Novartis-owned company.

You may also be interested in...



Four Biosimilar Pegfilgrastims Under EU Review After Sandoz Re-Submits Zioxtenzo

The EMA’s scientific committee, the CHMP, now has four biosimilar versions of Amgen’s neutropenia drug Neulasta (pegfilgrastim) under review, after Sandoz re-submitted its product at the end of October.

Four Biosimilar Pegfilgrastims Under EU Review After Sandoz Re-Submits Zioxtenzo

The EMA’s scientific committee, the CHMP, now has four biosimilar versions of Amgen’s neutropenia drug Neulasta (pegfilgrastim) under review, after Sandoz re-submitted its product at the end of October.

Biosimilar Trade Secrets: Coherus Hiring Of Amgen Exec Leads To Theft Suit

Three months before user fee date for Coherus' Neulasta (pegfilgrastim) biosimilar, Amgen claims company stole confidential information including pricing and contracting strategies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel